Zacks: Analysts Expect Strongbridge Biopharma plc (NASDAQ:SBBP) Will Post Earnings of -$0.15 Per Share

Analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to post ($0.15) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have issued estimates for Strongbridge Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.14). Strongbridge Biopharma reported earnings of ($0.25) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 40%. The firm is expected to report its next quarterly earnings results on Thursday, November 5th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.63). For the next financial year, analysts expect that the company will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.60) to ($0.39). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.08). The company had revenue of $7.76 million during the quarter, compared to analyst estimates of $6.11 million. Strongbridge Biopharma had a negative return on equity of 80.86% and a negative net margin of 205.02%.

Several analysts have recently weighed in on SBBP shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research note on Thursday, September 10th. Zacks Investment Research lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $5.00 target price on shares of Strongbridge Biopharma in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Strongbridge Biopharma has a consensus rating of “Buy” and a consensus target price of $8.05.

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in Strongbridge Biopharma in the 2nd quarter valued at approximately $48,000. Ieq Capital LLC purchased a new position in shares of Strongbridge Biopharma during the second quarter worth $79,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Strongbridge Biopharma during the second quarter worth $86,000. Cigna Investments Inc. New acquired a new stake in shares of Strongbridge Biopharma in the second quarter valued at $103,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Strongbridge Biopharma in the 1st quarter valued at $56,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Strongbridge Biopharma stock traded down $0.03 during midday trading on Wednesday, hitting $2.80. 421,624 shares of the stock were exchanged, compared to its average volume of 410,236. The company has a current ratio of 3.39, a quick ratio of 3.32 and a debt-to-equity ratio of 0.14. The stock’s 50-day simple moving average is $3.58 and its 200 day simple moving average is $3.10. Strongbridge Biopharma has a fifty-two week low of $1.43 and a fifty-two week high of $4.63. The stock has a market capitalization of $152.20 million, a price-to-earnings ratio of -2.34 and a beta of 1.54.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

See Also: Fundamental Analysis and Choosing Stocks

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with's FREE daily email newsletter.